Head and neck cancers usually begin in the squamous cells that line the moist, mucosal surfaces in the head and neck (for example, inside the mouth, the nose, and the throat). These squamous cell cancers are often referred to as squamous cell carcinomas of the head and neck.
The aim of the study is to evaluate quality of life in patients on concurrent chemo radiotherapy with cisplatin in head and neck cancer.
The objective of the study is to measure the quality of life and pharmaceutical care and toxicity profile of cisplatin with radiotherapy in head and neck cancer.
The methodology involves subjects, who satisfy the study category taken into study and patient consent form was taken. Subject information was collected using data collection forms and details of the subject were secured. FACT-H&N (Version 4) was filled by subject before and after the treatment.
Data collected by using questionnaire FACT- H&N for assessing the quality of life by using various scales such as emotional, additional, social, functional, and physical well being patients on concurrent chemoradiotherapy with cisplatin and P value found to be <0.0001and toxicity profile also studied, patients more suffered with weight loss, anemia, thrombocytopenia and neutropenia and radiation toxicity also found to be patients more suffered with dermatitis and mucositis.
Patients on CCRT have improved the quality of life rather than radiotherapy alone. Even toxicity also more with CCRT than radiotherapy.
Impact Factor
2022: 6.012
This work is licensed under a